KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

NCT03342937 | Completed Phase 2 Results DMC FDA Drug

• 1 other identifier: Pro00080566
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 7

Brief Summary

This study will be conducted in two stages: 1) safety validation and 2) dose expansion

1. 1.Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab, oxaliplatin and capecitabine. Five (5) subjects will be enrolled and their safety data after 21 days of treatment will be reviewed before additional subjects are enrolled. Subjects on this portion of the study will only be enrolled at the Duke Cancer Institute.
2. 2.Dose Expansion Cohort: The second portion of the study (ie. phase II) will enroll 30 subjects. In the dose expansion cohort, the first cycle will be modified to allow one week of pembrolizumab monotherapy before starting capecitabine and oxaliplatin (XELOX) chemotherapy, which will allow analysis of biomarkers related to pembrolizumab. Subjects on this portion of the study will be enrolled at the Duke Cancer institute and select external collaborating institutions.

Conditions

Gastric Cancer; Esophagus Cancer

Keywords

pembrolizumab; XELOX; gastric cancer

Outcome Measures

Primary Outcomes (1)

• Months of Progression-free Survival (PFS)

  PFS measured from study entry until documented progression or death from any cause. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Patients who have not experienced progression will be censored at the date of the last radiographic assessment. The median PFS will be estimated using the Kaplan-Meier method.

  Up to 44 months

Secondary Outcomes (2)

• Response Rate as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

  Up to 44 months

• Months of Overall Survival

  Up to 44 months

Study Arms (1)

Oxaliplatin+Capecitabine+Pembrolizumab

EXPERIMENTAL

Drug: Oxaliplatin+Capecitabine+Pembrolizumab

Interventions

Oxaliplatin+Capecitabine+Pembrolizumab DRUG

For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1. This study has 2 parts: 1. Safety validation part: all Cycles are 21 days in length. 2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.

Oxaliplatin+Capecitabine+Pembrolizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically and/or cytologically documented and radiographically measurable (by RECIST 1.1) adenocarcinoma of the esophagus or stomach (HER2-positive or negative) that is metastatic/recurrent and not amenable to potentially curative treatment
• No prior chemotherapy for metastatic/recurrent disease. Prior adjuvant or neo-adjuvant treatment with a fluoropyrimidine or fluoropyrimidine based regimen is allowed only if it is completed at least 6 months prior to the start of study drug, whether given alone or with radiation therapy. Patients who have received prior neo-adjuvant therapy (chemotherapy and/or radiation therapy) which did not contain 5-FU or capecitabine and have been diagnosed with metastatic disease (with no previous treatment in the metastatic setting) are eligible. No 6-months window is required for these patients. In the setting of metastatic disease requiring local palliation, only radiosensitizing doses of 5-FU or capecitabine monotherapy are permitted.
• Prior radiation therapy is permitted, provided is completed at least 28 days prior to the start of study drug.
• Age ≥ 18 years with ability to understand and willingness to provide informed consent.
• ECOG performance status of 0 or 1.
• Adequate organ and marrow function as defined below by the following:
• Absolute neutrophil count (ANC) ≥ 1500 µl
• Platelets ≥ 100,000/µl
• Hemoglobin (Hgb) ≥ 9 g/dL
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
• AST/ALT ≤ 2 x ULN without liver metastasis; ≤ 5 x ULN with liver metastasis
• Creatinine clearance ≥ 50 cc/min

You may not qualify if:

• Prior therapy with an anti-PD-1, anti PD-L1, anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents.
• Chemotherapy, targeted small molecule therapy, radiotherapy, experimental agents, prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents, or biological cancer therapy (including monoclonal antibodies) within 14 days prior to the start of study drug, or not recovered (≤ grade 1 or baseline) from adverse events due to a previously administered agent.
• Known CNS metastases and/or carcinomatous meningitis. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 30 days prior to the start of study drug.
• Documented history of clinically significant autoimmune disease (other than well-controlled hypothyroidism) or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo, type I diabetes mellitus, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• Receiving systemic steroid therapy or any form of immunosuppressive therapy within 1 week prior to the start of study drug.
• Received a live vaccine within 4 weeks prior to the start of the study drug.
• Has known history of, or any evidence of active, non-infectious pneumonitis.
• Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible.
• Pregnant or breastfeeding
• Not willing to use an effective method of birth control
• Concurrent severe and/or uncontrolled medical conditions, which may compromise participation in the study, including impaired heart function or clinically significant heart disease.
• Current use of medication specified by the protocol as prohibited for administration in combination with the study drug. This includes patients with a condition requiring systemic treatment with either corticosteroids (\>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the start of study drug. Inhaled or topical steroids and adrenal replacement doses \> 10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Recent or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment within 2 weeks prior to the start of study drug.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the start of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study (except fot rhe planned metastatectomy).
• Serious, non-healing wound, ulcer, or bone fracture.

Sponsors & Collaborators

• Duke University: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (7)

Johnston Health Services Corporation

Clayton, North Carolina, 27520, United States

Location

Duke Cancer Center, Duke University

Durham, North Carolina, 27710, United States

Location

Maria Parham Healthcare Association

Henderson, North Carolina, 27536, United States

Location

Scotland Health Care System

Laurinburg, North Carolina, 28352, United States

Location

Southeastern Regional Medical Center

Lumberton, North Carolina, 28358, United States

Location

Johnston Health Services Corporation

Smithfield, North Carolina, 27577, United States

Location

Lexington Medical Center

West Columbia, South Carolina, 29169, United States

Location

MeSH Terms

Conditions

Stomach Neoplasms; Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Head and Neck Neoplasms; Esophageal Diseases

Results Point of Contact

• Title: Dr. Hope Uronis
• Organization: Duke University

hope.uronis@duke.edu

919-668-1861

Study Officials

• Hope Uronis, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 10, 2017
• First Posted: November 17, 2017
• Study Start: January 11, 2018
• Primary Completion: February 6, 2023
• Study Completion: February 6, 2023
• Last Updated: March 13, 2024
• Results First Posted: March 13, 2024

Record last verified: 2024-02

Locations

US (7)